Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia

This is an open-label, multi-cohort, investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of GI001 in adult patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL) and B-cell Acute Lymphoblastic Leukemia (R/R B-ALL). GI001 is an exploratory, in vivo chimeric antigen receptor T-cell (CAR-T) therapy targeting the CD19 antigen. Unlike traditional CAR-T cell therapies that require extensive in vitro cell manufacturing, GI001 is administered directly to the patient via intravenous infusion, aiming to generate CAR-T cells

Trial Details

NCT ID
NCT07862010
Phase
EARLY_PHASE1
Sponsor
Hematology department of the 920th hospital
Status
RECRUITING
Cancer Type
Burkitt Lymphoma Lymphoma
Interventions
  • GI001
Locations (sample)
  • Yunnan, Kunming, China|29.12312,110.14692

Key Eligibility Criteria

  • 1\. Age 18 to 75 years, inclusive.
  • 2\. Diagnosis of CD19-positive relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) or R/R B-cell acute lymphoblastic leukemia (B-ALL):
  • 1 CD19-positive R/R B-NHL meeting the following:
  • Histopathologic diagnosis of indolent NHL (iNHL), including but not limited to follicular lymphoma (FL) and marginal zone lymphoma (MZL), or small …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Burkitt Lymphoma Lymphoma Trials on Trialify →